S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
The 3-Stock Retirement Blueprint (Ad)
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
Moldova signs new energy deal that could ease blackout risk
Why Your IRA Could Crash on January 16th? (Ad)
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC+ oil producers face uncertainty over Russian sanctions
Why Your IRA Could Crash on January 16th? (Ad)
OPEC keeps oil targets amid uncertainty on Russian sanctions
FDA change ushers in cheaper, easier-to-get hearing aids
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
The 3-Stock Retirement Blueprint (Ad)
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
Moldova signs new energy deal that could ease blackout risk
Why Your IRA Could Crash on January 16th? (Ad)
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC+ oil producers face uncertainty over Russian sanctions
Why Your IRA Could Crash on January 16th? (Ad)
OPEC keeps oil targets amid uncertainty on Russian sanctions
FDA change ushers in cheaper, easier-to-get hearing aids
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
The 3-Stock Retirement Blueprint (Ad)
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
Moldova signs new energy deal that could ease blackout risk
Why Your IRA Could Crash on January 16th? (Ad)
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC+ oil producers face uncertainty over Russian sanctions
Why Your IRA Could Crash on January 16th? (Ad)
OPEC keeps oil targets amid uncertainty on Russian sanctions
FDA change ushers in cheaper, easier-to-get hearing aids
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
The 3-Stock Retirement Blueprint (Ad)
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
Moldova signs new energy deal that could ease blackout risk
Why Your IRA Could Crash on January 16th? (Ad)
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC+ oil producers face uncertainty over Russian sanctions
Why Your IRA Could Crash on January 16th? (Ad)
OPEC keeps oil targets amid uncertainty on Russian sanctions
FDA change ushers in cheaper, easier-to-get hearing aids
NASDAQ:COLL

Collegium Pharmaceutical - COLL Earnings Date, Estimates & Call Transcripts

$23.02
+0.14 (+0.61%)
(As of 12/2/2022 12:00 AM ET)
Add
Compare
Today's Range
$22.36
$23.27
50-Day Range
$15.46
$23.02
52-Week Range
$14.04
$23.27
Volume
284,311 shs
Average Volume
249,842 shs
Market Capitalization
$772.78 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$32.75
Skip Charts & View Estimated and Actual Earnings Data

COLL Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

COLL Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Collegium Pharmaceutical Analyst Forecasts

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany Guidance
Q1 20222$0.86$0.88$0.87 
Q2 20222$0.92$1.29$1.11 
Q3 20222$1.04$1.42$1.23 
Q4 20222$1.15$1.51$1.33 
FY 20228$3.97$5.10$4.54 
Q1 20231$2.05$2.05$2.05 
Q2 20231$2.04$2.04$2.04 
Q3 20231$2.08$2.08$2.08 
Q4 20231$2.19$2.19$2.19 
FY 20234$8.36$8.36 $8.36

COLL Earnings Date and Information

Collegium Pharmaceutical has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 23rd, 2023 based off prior year's report dates.

Collegium Pharmaceutical Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
2/23/2023
(Estimated)
        
8/4/2022Q2 2022$1.15($0.04)($1.19)$0.07$122.63 million$123.55 million
5/10/2022Q1 2022$0.82$0.42($0.40)$1.23$78.67 million$83.80 million    
2/24/2022Q4 2021$0.86($0.73)($1.59)($0.73)$80.75 million$27.36 million
11/4/20219/30/2021$0.75$0.22($0.53)$0.22$84.65 million$78.80 million    
8/5/2021Q2 2021$0.34$0.27($0.07)($1.25)$84.29 million$82.94 million  
5/6/20213/31/2021$0.30$0.41+$0.11$0.41$81.21 million$87.70 million  
2/25/202112/31/2020$0.29$0.20($0.09)$0.20$76.77 million$76.27 million  
11/5/20209/30/2020$0.90$0.32($0.58)$0.32$77.39 million$77.40 million  
8/5/20206/30/2020$0.24$0.23($0.01)$0.23$74.87 million$78.06 million  
5/7/20203/31/2020$0.66$0.01($0.65)$0.01$76.64 million$76.51 million  
2/27/2020Q4 2019($0.17)($0.07)+$0.10($0.07)$73.31 million$74.20 million  
11/6/2019Q3($0.15)($0.18)($0.03)($0.18)$74.32 million$72.94 million  
8/7/2019Q2 2019($0.19)($0.1411)+$0.0489($0.14)$75.77 million$75.04 million  
5/8/20193/31/2019($0.30)($0.29)+$0.01($0.29)$70.10 million$74.52 million  
2/27/2019Q4 2018($0.38)$0.27+$0.65$0.27$72.71 million$73.40 million  
11/8/20189/30/2018($0.36)($0.50)($0.14)($0.50)$74.79 million$70.20 million  
8/8/2018Q2 2018($0.42)($0.40)+$0.02($0.12)$72.21 million$73.10 million
5/9/2018Q1 2018($0.55)($0.57)($0.02)($0.57)$51.92 million$63.70 million
3/7/2018Q4 2017($0.56)($0.54)+$0.02($0.54)$9.88 million$10.79 million  
11/8/2017Q3 2017($0.73)($0.45)+$0.28($0.45)$5.31 million$11.95 million
8/9/2017Q2 2017($0.81)($0.72)+$0.09($0.72)$4.07 million$3.56 million  
5/10/2017Q1 2017($0.9760)($0.79)+$0.1860($0.79)$3.55 million$2.17 million
3/9/2017Q4 2016($1.07)($1.02)+$0.05($1.02)$1.79 million$1.30 million  
11/10/2016Q3 2016($1.09)($1.13)($0.04)($1.13)$1.00 million$0.41 million  
8/10/2016Q2($0.7580)($1.05)($0.2920)($1.05)$0.16 million  
5/10/2016Q1($0.60)($0.68)($0.08)($0.68)  
3/15/2016Q415($0.45)($0.46)($0.01)($0.46)  
11/12/2015Q315($0.30)($0.46)($0.16)($0.46)  
8/12/2015Q215($0.26)($0.45)($0.19)($0.45)  












Collegium Pharmaceutical Earnings - Frequently Asked Questions

When is Collegium Pharmaceutical's earnings date?

Collegium Pharmaceutical has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 23rd, 2023 based off last year's report dates. Learn more on COLL's earnings history.

How much revenue does Collegium Pharmaceutical generate each year?

Collegium Pharmaceutical (NASDAQ:COLL) has a recorded annual revenue of $276.87 million.

How much profit does Collegium Pharmaceutical generate each year?

Collegium Pharmaceutical (NASDAQ:COLL) has a recorded net income of $71.52 million. COLL has generated -$1.26 earnings per share over the last four quarters.

What is Collegium Pharmaceutical's price-to-earnings ratio?

Collegium Pharmaceutical (NASDAQ:COLL) has a forward price-to-earnings ratio of 6.26. The price/earnings-to-growth ratio is 0.31.

What is Collegium Pharmaceutical's EPS forecast for next year?

Collegium Pharmaceutical's earnings are expected to grow from $3.68 per share to $5.24 per share in the next year, which is a 42.39% increase.

More Earnings Resources from MarketBeat

Upcoming Earnings:
This page (NASDAQ:COLL) was last updated on 12/4/2022 by MarketBeat.com Staff